PHEROMONE SCIENCES CORP. (the "Company") (TSX VENTURE: PHS) is pleased to announce that it has received TSX Venture approval to proceed with the Company's previously announced joint venture and financing agreement with Sertonex Inc. (Sertonex) of London Ontario and Sertoli Technologies Inc. (STI) of Tucson Arizona. The purpose of the joint venture is to develop a commercially viable treatment for Type 1 human diabetes using transplanted devices containing pig cells. The Company intends to exercise its option under the terms of the agreement and to begin the research project.
